4 recruiting, 1 active not recruiting, 1 not yet recruiting. 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Active not recruiting 1, Not yet recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Unresectable Biliary Tract Carcinoma: new trials by email Literature Review of Unresectable Biliary Tract Carcinoma trials Research Report on Unresectable Biliary Tract Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma Envafolimab and Surufatinib - Unresectable Biliary Tract Carcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2024-10-01 | 2024-10-24 |
| Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma Adebrelimab, Apatinib, gemcitabine and cisplatin - Unresectable Biliary Tract Carcinoma | Phase 2 | Recruiting | Henan Cancer Hospital | 63 | 2024-04-01 | 2024-12-27 |
| Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Binimetinib, Biopsy Procedure, Biospecimen Collection - Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2024-02-09 | 2026-10-19 |
| Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers Tripegfilgrastim - Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma | Phase 2 | Recruiting | National Cancer Center, Korea | 98 | 2024-01-16 | 2025-06-18 |
| Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients Trastuzumab, Chemotherapy - Biliary Tract Cancer, HER2-positive Cancer | Phase 3 | Recruiting | Tata Memorial Centre | 220 | 2023-07-21 | 2025-07-14 |
Cholangiocarcinoma (2) · Gallbladder Neoplasms (2) · Biliary Tract Neoplasms (1) · Klatskin Tumor (1)
Biliary Tract Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Adenocarcinoma (2) · Biliary Tract Neoplasms (2) · Carcinoma (2) · Gallbladder Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2)
Cisplatin (3) · Gemcitabine (3) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1) · Biopsy (1) · Disulfides (1) · Drug Therapy (1) · Fluorouracil (1) · Immunoglobulin G (1) · Leucovorin (1) · Oxaliplatin (1) · Platinum (1) · Trastuzumab (1)
Henan Cancer Hospital (1) · National Cancer Center, Korea (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1) · Tata Memorial Centre (1) · Tianjin Medical University Cancer Institute and Hospital (1)
United States (2) · China (1) · India (1) · South Korea (1)
Ardaman Shergill (1) · Sameek Roychowdhury, MD, PhD (1) · Sangmyung Woo, M.D (1) · Vikas Ostwal, DM (1) · Ying Liu, MD (1)
PMID 25576433, PMID 26615328, PMID 30178032, PMID 3085974, PMID 30998813, PMID 31489036, PMID 33120908, PMID 34368921, PMID 34656226, PMID 35289915, PMID 35715440, PMID 36062047, PMID 497341
U10CA180821 (1)